Mesothelioma.com Resources for Patients and their Families

Mesothelioma Doctors

Brian W. Loggie, M.D.

Dr. Loggie
Omaha, NE

Dr. Brian W. Loggie

Chief, Division of Surgical Oncology

Creighton University Medical Center

Alegent Creighton Clinic Surgical Oncology
601 North 30th Street #2803
Omaha, NE 68131
(402) 280-5292

Loyola College, Montreal, Canada - 1974

McGill University, Montreal, Canada - 1979

Montreal General Hospital, Montreal, Canada (1980-1986)

University of Illinois at Chicago, Chicago, Illinois (1986-1988)

Overview

Dr. Brian W. Loggie currently serves as the Harold J. Bonnstetter Professor of Surgery at Creighton University School of Medicine located in Omaha, Nebraska and is chief of the division of surgical oncology and director of the Cancer Biology Program at Creighton University Medical Center. Dr. Loggie attended Loyola College in Montreal, Canada prior to completing his medical degree at McGill University, also located in Montreal. He completed his residency at Montreal General Hospital from 1980-1986 followed by a clinical and research fellowship in surgical oncology at the University of Illinois at Chicago from 1986-1988.

Prior to assuming his leadership roles at Creighton in 2002, Dr. Loggie held faculty positions at the University of Illinois at Chicago (1986-1988), the Bowman Gray School of Medicine in Winston-Salem, North Carolina (1988-2000), and the University of Texas Southwestern Medical Center in Dallas, Texas (2000-2002).

Professional Highlights

Dr. Loggie is internationally-renowned for his expertise and clinical experience in treating cancers that are metastatic to or that have originated in the peritoneal lining (thin tissue layer) of the abdomen and pelvis. He is a pioneer in the use of hyperthermic intraperitoneal chemotherapy (HIPEC) treatment—a procedure in which a chemotherapy solution is heated to a temperature greater than normal body temperature and delivered directly to the abdominal cavity.

Board-certified by the American Board of Surgery, Dr. Loggie is an expert in surgical oncology. Among the conditions that he specializes in are peritoneal mesothelioma, peritoneal carcinomatosis and malignant ascites, cutaneous malignant melanoma, pseudomyxoma peritonei, and abdominopelvic and retroperitoneal sarcomas.

Dr. Loggie is a fellow of the Royal College of Surgeons of Canada, the Society of Surgical Oncology (SSO), the American College of Surgeons (ACS), and the Southeastern Surgical Congress (SESC). His professional societal memberships include, but are not limited to, the Canadian Association of General Surgeons (CAGS), the Association for Academic Surgery (AAS), the American Medical Association (AMA), the Southern Association for Oncology (SAO), and the American Society of Clinical Oncology (ASCO).

Clinical Research and Publications

Dr. Loggie has assembled a clinical and translational research team at Creighton with a particular focus on identifying innovative and more effective treatments for malignant peritoneal mesothelioma and pseudomyxoma peritonei (PMP)—a rare and slow-growing form of cancer that usually originates in the appendix or ovaries.

Dr. Loggie has coauthored several scientific, peer-reviewed articles that have been published in such journals as The American Surgeon, the Journal of Surgical Oncology, World Journal of Surgical Oncology, Annals of Surgical Oncology, among others. Articles that he is coauthored with a particular focus on mesothelioma include the following:

  • Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg. 2014 Apr;80(4):348-52.
  • Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK, Loggie BW. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol. 2010 Oct 13;8:88.
  • Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol. 2009 Jan;16(1):152-8. Epub 2008 Nov 8.
Sources

Sources

Creighton University School of Medicine
http://medschool.creighton.edu/somfaculty/loggie/contact/

Mesothelioma Doctors by State
  • Top Doctors and Clinics
  • Clinical Trial Information
  • Delivered within 24 hrs

Yes   No

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: